Soligenix Reports Positive Phase 2a Results for SGX302 Gel Formulation in Mild-to-Moderate Psoriasis
核心洞察
Soligenix's optimized gel formulation of SGX302 (synthetic hypericin) demonstrated clinical success in Cohort 3 of its Phase 2a psoriasis (搜索) trial, with one patient achieving "Almost Clear" status and over 50% PASI score improvement.
The photodynamic therapy uses safe visible light activation and was well tolerated with no drug-related adverse events, potentially offering a non-carcinogenic alternative to current UV-based treatments.
The global psoriasis (搜索) treatment market is valued at approximately $15 billion in 2020 and projected to reach $40 billion by 2027, with 60-125 million people worldwide living with the condition.
Soligenix announced positive results from the third cohort of its ongoing Phase 2a trial evaluating SGX302 (synthetic hypericin) for mild-to-moderate psoriasis (搜索), demonstrating clinical success with an optimized gel formulation that improved patient experience and treatment outcomes.
Enhanced Gel Formulation Shows Clinical Promise
The Cohort 3 extension enrolled four patients treated with an improved topical gel formulation of synthetic hypericin over an 18-week period. The gel formulation was specifically designed to improve ease of application to larger skin areas compared to the previous ointment format. Among the three evaluable patients (one discontinued for personal reasons), one achieved "Almost Clear" status using the Investigator Global Assessment (IGA), considered a standard clinical measure for treatment success in psoriasis (搜索), with substantial PASI score improvement exceeding 50%.
All evaluable patients demonstrated improvements across multiple assessment measures, including the Investigator Global Assessment, Psoriasis (搜索) Activity and Severity Index (PASI), simplified psoriasis index, dermatology life quality index, and Skindex-29 questionnaire. The treatment was well tolerated with no drug-related adverse events identified.
Novel Photodynamic Therapy Mechanism
SGX302 represents a first-in-class photodynamic therapy utilizing visible light-activated synthetic hypericin. The treatment involves topical application of the photosensitizer to skin lesions, where it is absorbed by cutaneous T-cells (搜索). Subsequent activation by safe, visible light in the red-yellow spectrum induces T-cell apoptosis, addressing the root cause of psoriasis (搜索) lesions.
This approach offers potential advantages over existing photodynamic therapies that rely on ultraviolet light, which carries long-term safety concerns including secondary malignancies. The visible light penetrates deeper into skin tissue, potentially treating thicker plaques and lesions more effectively while avoiding the carcinogenic risks associated with UV exposure.
Comprehensive Trial Results Across Cohorts
The Phase 2a study has enrolled patients across three cohorts with progressive treatment optimization. Cohort 1's five patients received twice-weekly treatment with 0.25% hypericin ointment followed by light activation, with light doses increased up to 1 J/cm² until mild erythema was observed. While patients showed biological improvement in PASI scores, none met the treatment success definition at 18 weeks.
Cohort 2 implemented accelerated light treatment with dose increases up to 2 J/cm² per visit, reaching maximum light dose (25 J/cm²) by week 14. Two of four evaluable patients achieved clinical success scores during treatment, with all patients improving and achieving approximately 50% average PASI score reduction.
Significant Market Opportunity
According to Christopher J. Schaber, PhD, President and CEO of Soligenix, the psoriasis (搜索) indication represents a substantial market opportunity with 60-125 million people worldwide living with the condition. The global psoriasis treatment market was valued at approximately $15 billion in 2020 and is projected to reach $40 billion by 2027.
Psoriasis (搜索) affects an estimated 3% of the U.S. population, or more than 7.5 million people, with approximately 80% having mild-to-moderate disease. The condition significantly impacts quality of life and is associated with cardiovascular, arthritic, and metabolic diseases, as well as psychological conditions including anxiety, depression, and suicide risk.
Broader Development Strategy
The success builds on Soligenix's experience with synthetic hypericin in cutaneous T-cell lymphoma (搜索) (CTCL (搜索)), where HyBryte™ demonstrated efficacy in Phase 3 trials with 42% treatment response rate for plaque lesions (p<0.0001) and 37% for patch lesions (p=0.0009) after 12 weeks of treatment. A published Phase 1/2 proof-of-concept study showed 80% response rate in psoriasis (搜索) patients (p<0.02).
Soligenix anticipates continuing SGX302 development in psoriasis (搜索) while advancing its confirmatory Phase 3 trial for HyBryte™ in early-stage CTCL (搜索) treatment, with topline results expected in the second half of 2026. The company's approach targets dysregulated T-cells (搜索) common to both conditions, potentially offering safer alternatives to current immunosuppressive treatments that carry infection and cancer risks.